School of Nursing, Fudan University, 305 Fenglin Road, Shanghai, 200032, China.
BMC Womens Health. 2023 Mar 10;23(1):100. doi: 10.1186/s12905-023-02256-9.
Both contextual and cancer-related factors could be identified as causes of the interindividual variability observed for symptoms experienced during breast cancer treatment with chemotherapy. Understanding age differences and the predictors of latent class memberships for symptom heterogeneity could contribute to personalized interventions. This study aimed to identify the role of age differences on cancer-related symptoms in women undergoing chemotherapy for breast cancer in China.
A cross‑sectional survey was conducted among patients with breast cancer in three tertiary hospitals in central China between August 2020 to December 2021. The outcomes of this study included sociodemographic and clinical characteristics, Patient-Reported Outcomes Measurement Information System (PROMIS)-57 and PROMIS-cognitive function short form scores.
A total of 761 patients were included, with a mean age of 48.5 (SD = 11.8). Similar scores were observed across age groups for all symptoms except for fatigue and sleep disturbance domains. The most central symptoms varied among each group, and were fatigue, depression, and pain interference for the young-aged, middle-aged, and elderly-aged groups, respectively. In the young-aged group, patients without health insurance (OR = 0.30, P = 0.048) and in the fourth round of chemotherapy or above (OR = 0.33, P = 0.005) were more likely to belong to low symptom classes. In the middle-aged group, patients in menopause (OR = 3.58, P = 0.001) were more likely to belong to high symptom classes. In the elderly-aged group, patients with complications (OR = 7.40, P = 0.003) tended to belong to the high anxiety, depression, and pain interference classes.
Findings from this study indicated that there is age-specific heterogeneity of symptoms present for Chinese women being treated for breast cancer with chemotherapy. Tailored intervention should consider the impact of age to reduce patients' symptom burdens.
在接受化疗治疗乳腺癌的过程中，个体间的症状差异可归因于上下文和癌症相关因素。了解年龄差异和预测症状异质性的潜在类别成员身份，有助于实施个性化干预。本研究旨在确定年龄差异对中国接受化疗的乳腺癌女性癌症相关症状的影响。
2020 年 8 月至 2021 年 12 月，在华中地区的三家三级医院中进行了一项针对乳腺癌患者的横断面调查。本研究的结局包括社会人口学和临床特征、患者报告结局测量信息系统（PROMIS）-57 和 PROMIS 认知功能简短量表评分。
共纳入 761 例患者，平均年龄为 48.5（SD=11.8）岁。除疲劳和睡眠障碍领域外，各年龄组的所有症状评分相似。各年龄组的主要中心症状不同，年轻、中年和老年组分别为疲劳、抑郁和疼痛干扰。在年轻组中，无医疗保险（OR=0.30，P=0.048）和接受第四轮或以上化疗（OR=0.33，P=0.005）的患者更有可能属于低症状类别。在中年组中，处于绝经期的患者（OR=3.58，P=0.001）更有可能属于高症状类别。在老年组中，有并发症的患者（OR=7.40，P=0.003）更有可能属于高焦虑、抑郁和疼痛干扰类别。
本研究结果表明，接受化疗治疗乳腺癌的中国女性存在特定年龄的症状异质性。有针对性的干预措施应考虑年龄的影响，以减轻患者的症状负担。
Zotero 插件
